Literature DB >> 17300564

Outcomes in retinoblastoma, 1974-2005: the Children's Hospital, Westmead.

Edwina L Berman1, Craig E Donaldson, Michael Giblin, Frank J Martin.   

Abstract

BACKGROUND: To report the 31-year experience of outcomes in retinoblastoma from a single centre.
METHODS: A retrospective analysis of consecutive cases of retinoblastoma diagnosed and treated at the Westmead Children's Hospital, Sydney between 1974 and 2005 was performed. The subjects were analysed as two groups: those diagnosed between 1974 and 1989 (series alpha) and those diagnosed between 1990 and 2005 (series beta).
RESULTS: There were a total of 142 patients included in the study, with a median follow up of 72 months. There were 84 patients with unilateral disease and 58 patients (116 eyes) with bilateral disease. The total enucleation rate remained high throughout both series for those with unilateral disease: 89% (series alpha) and 95% (series beta). There was a reduction in enucleations performed for those with bilateral disease from 68.4% (series alpha) to 43.6% (series beta) (P < 0.025). There were no bilateral enucleations performed after 1995. Actuarial Kaplan-Meier curves showed that 56% of all preserved eyes had not recurred at a median follow up of 95 months and 78.1% had avoided enucleation. Overall 43% of preserved eyes attained a visual acuity better than or equal to 6/12 and 55% achieved a visual acuity better than 6/60. There were four deaths due to retinoblastoma. Five patients were diagnosed with a second non-ocular malignancy. The most common treatment-related complications were cataracts, facial deformity, sepsis and febrile neutropaenia.
CONCLUSIONS: The introduction of newer globe-preserving treatments for retinoblastoma was associated with equivalent visual outcomes, stable mortality rate and a greater number of short-term complications but avoided the late side-effects associated with external beam radiotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17300564     DOI: 10.1111/j.1442-9071.2006.01386.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  16 in total

1.  Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Christina Decatur; Timothy G Murray; Samuel K Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

2.  Compliance in retinoblastoma.

Authors:  Sameer Bakhshi; Shikha Gupta; Varun Gogia; Yaddanapuddi Ravindranath
Journal:  Indian J Pediatr       Date:  2010-03-19       Impact factor: 1.967

3.  Characteristics and clinical presentations of pediatric retinoblastoma in North-western Iran.

Authors:  Reza Nabie; Nazli Taheri; Ali Mahdavi Fard; Rohollah Fadaei Fouladi
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

4.  Clinical presentation of retinoblastoma in Malaysia: a review of 64 patients.

Authors:  S C Reddy; S Anusya
Journal:  Int J Ophthalmol       Date:  2010-03-18       Impact factor: 1.779

5.  Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Hinda Boutrid; Magda Celdran; William Feuer; Wei Shi; Eleut Hernandez; Theodore J Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-11       Impact factor: 4.799

6.  Presentation of retinoblastoma at a paediatric eye clinic in ghana.

Authors:  V Essuman; C T Ntim-Amponsah; S Akafo; L Renner; L Edusei
Journal:  Ghana Med J       Date:  2010-03

7.  Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Authors:  Yolanda Piña; Hinda Boutrid; Timothy G Murray; Martine J Jager; Colleen M Cebulla; Amy Schefler; Long V Ly; Armando Alegret; Magda Celdran; William Feuer; Maria-Elena Jockovich
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

8.  "Retinoblastoma survival disparity": The expanding horizon in developing countries.

Authors:  Masood Naseripour
Journal:  Saudi J Ophthalmol       Date:  2012-02-18

Review 9.  Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis.

Authors:  Anthony B Daniels; Shriji N Patel; Ronald W Milam; Sahar Kohanim; Debra L Friedman; Tatsuki Koyama
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

10.  Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

Authors:  Y Piña; C Decatur; Tg Murray; Sk Houston; D Gologorsky; M Cavalcante; L Cavalcante; E Hernandez; M Celdran; W Feuer; T Lampidis
Journal:  Clin Ophthalmol       Date:  2011-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.